Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which Second-Line drug works best for axial spondyloarthritis? a trial aims to find out

NCT ID NCT07770646

Disease control Sponsor: The University of Texas Health Science Center, Houston Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This trial tests two different types of drugs—an IL-17 inhibitor (secukinumab) and a JAK inhibitor (upadacitinib)—in people with axial spondyloarthritis who have not improved with a TNF inhibitor. The goal is to see which approach is more effective at reducing disease activity over 16 weeks, and to check if a larger study is feasible. Participants will receive either weekly injections of secukinumab or daily oral upadacitinib, with regular assessments of symptoms and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Secukinumab (IL-17 inhibitor) and upadacitinib (JAK inhibitor)
What this could lead to
If successful, this trial could guide doctors on which second-line treatment works best for axial spondyloarthritis when the first biologic fails, improving symptom control and quality of life.
What could go wrong
This is a small pilot study, so results may not be definitive. Both drugs carry risks like infections, and the trial may not show a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * fulfill ASAS classification criteria for axSpA and/or modified New York classification criteria for AS * Active axSpA (ASDAS ≥ 2.1 and/or BASDAI ≥ 4) * Failure of or intolerance to ≥1 TNF * Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication * Ability to provide informed consent Exclusion Criteria: * Previously received an IL-17i or JAKi * Active infection requiring antimicrobials * Contraindications to either treatment arm: * Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis * Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN) * History of stroke, heart attack, or blood clots (venous or arterial) * Cirrhosis * End-stage renal disease (GFR \<15) or dialysis * Human Immunodeficiency Virus (HIV) positive * Pregnant or lactating * Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Axial spondyloarthritis (axspa) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Axial spondyloarthritis (axspa)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Texas health Science Center at Houston

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.